CN214374840U - Device for detecting blood coagulation characteristics - Google Patents
Device for detecting blood coagulation characteristics Download PDFInfo
- Publication number
- CN214374840U CN214374840U CN202021560467.9U CN202021560467U CN214374840U CN 214374840 U CN214374840 U CN 214374840U CN 202021560467 U CN202021560467 U CN 202021560467U CN 214374840 U CN214374840 U CN 214374840U
- Authority
- CN
- China
- Prior art keywords
- blood
- sample
- coagulation
- unit
- blood sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000023555 blood coagulation Effects 0.000 title claims abstract description 58
- 210000004369 blood Anatomy 0.000 claims abstract description 177
- 239000008280 blood Substances 0.000 claims abstract description 177
- 238000006243 chemical reaction Methods 0.000 claims abstract description 48
- 230000015271 coagulation Effects 0.000 claims abstract description 24
- 238000005345 coagulation Methods 0.000 claims abstract description 24
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 21
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 18
- 238000004458 analytical method Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 9
- 238000004364 calculation method Methods 0.000 claims abstract description 7
- 230000002429 anti-coagulating effect Effects 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 35
- 239000012528 membrane Substances 0.000 claims description 30
- 239000001509 sodium citrate Substances 0.000 claims description 22
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 22
- 230000010100 anticoagulation Effects 0.000 claims description 17
- 238000007781 pre-processing Methods 0.000 claims description 15
- 159000000007 calcium salts Chemical class 0.000 claims description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 8
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- 239000002033 PVDF binder Substances 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 239000003365 glass fiber Substances 0.000 claims description 3
- 239000002861 polymer material Substances 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 claims description 2
- 238000005259 measurement Methods 0.000 abstract description 21
- 239000000523 sample Substances 0.000 description 121
- 238000012360 testing method Methods 0.000 description 62
- 108010049003 Fibrinogen Proteins 0.000 description 24
- 102000008946 Fibrinogen Human genes 0.000 description 24
- 229940012952 fibrinogen Drugs 0.000 description 24
- 108090000190 Thrombin Proteins 0.000 description 16
- 229960004072 thrombin Drugs 0.000 description 16
- 230000006870 function Effects 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 108010094028 Prothrombin Proteins 0.000 description 9
- 102100027378 Prothrombin Human genes 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 229940039716 prothrombin Drugs 0.000 description 9
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 8
- 108010000499 Thromboplastin Proteins 0.000 description 8
- 102000002262 Thromboplastin Human genes 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- 229950003499 fibrin Drugs 0.000 description 8
- 102000009123 Fibrin Human genes 0.000 description 7
- 108010073385 Fibrin Proteins 0.000 description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 230000035602 clotting Effects 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- JXRVKYBCWUJJBP-UHFFFAOYSA-L calcium;hydrogen sulfate Chemical compound [Ca+2].OS([O-])(=O)=O.OS([O-])(=O)=O JXRVKYBCWUJJBP-UHFFFAOYSA-L 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000000624 ear auricle Anatomy 0.000 description 2
- 230000006624 extrinsic pathway Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000006623 intrinsic pathway Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000010339 medical test Methods 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000031915 positive regulation of coagulation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000009642 citrate test Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940081104 fibrinogen / thrombin Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model provides a detect device of blood coagulation characteristic of blood sample, it includes: a blood sample receiving and pretreatment unit, wherein said blood pretreatment member is for removing or counteracting the anticoagulant effect of an artificially added anticoagulant present in the blood sample; a reaction unit in which blood produces a coagulation process; a blood coagulation property analysis calculation unit operable to detect an electrical signal passing through the blood sample for a measurement duration to obtain a plurality of measurement results of a measurement function representing time; and a result presentation unit.
Description
Technical Field
The utility model relates to a medical equipment for examining blood coagulation characteristic.
Background
In the field of medical testing and research, in the testing of blood, after a blood sample (e.g., blood at the tip of an ear lobe or a fingertip, venous blood) is obtained from a subject, in order to prevent the blood sample from coagulating during storage or transfer, the blood is usually subjected to an anticoagulation treatment, such as artificial addition of an anticoagulation agent such as sodium citrate. Thus, the blood sample may be anticoagulated with an artificially added anticoagulant.
In clinical tests and routine screening, blood coagulation screening tests are required, including detection of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Activated Clotting Time (ACT), fibrinogen content (FIB), and Thrombin Time (TT, Thrombin Time). Various detection instruments have been provided in the art to examine the type of blood coagulation property under specific conditions by clinical laboratories, health practitioners, and the like.
However, existing test systems and instruments for detecting prothrombin time/activated partial thromboplastin time/fibrinogen/thrombin time have certain drawbacks. Because the test sample commonly used in the hospital clinical laboratory is anticoagulated blood, such as sodium citrate anticoagulation, the sample contains the anticoagulation agent to prevent the sample coagulation process, so that the anticoagulation cannot be directly tested on the existing instrument.
There is also a need in the art for an apparatus and method that can rapidly test the four coagulation indices prothrombin time, activated partial thromboplastin time, fibrinogen, thrombin time directly using anticoagulated whole blood, such as sodium citrate anticoagulated whole blood.
SUMMERY OF THE UTILITY MODEL
The utility model provides a detect device of blood coagulation characteristic of blood sample, it includes:
the blood sample receiving and preprocessing unit comprises a blood preprocessing part, a sample adding hole and a conveying channel connected with the reaction unit;
and
a reaction unit in which blood produces a coagulation process.
Wherein the blood enters the sample adding hole after passing through the blood pretreatment member of the blood sample receiving and pretreatment unit, and then is transferred to the reaction unit through the transfer channel connected to the reaction unit, wherein the blood generates a coagulation process.
In one aspect of the present invention, the apparatus for detecting blood coagulation characteristics of a blood sample further comprises:
a blood coagulation property analyzing and calculating unit which can obtain a measurement result related to the blood coagulation property according to a signal displayed by the blood in the coagulation process in the reaction unit;
and/or
And a result presenting unit.
In one aspect of the present invention, the blood sample receiving and preprocessing unit and the reaction unit of the above-mentioned device for detecting blood coagulation property of blood sample exist in a form independent from other parts of the device, such as a test cartridge (e.g., in a chip form) that can be inserted into an instrument (e.g., an instrument including the blood coagulation property analysis calculating unit and/or the result presenting unit).
In one aspect of the present invention, the blood sample receiving and preprocessing unit and the reaction unit of the above device for detecting blood coagulation property of blood sample are integrated with other parts of the device (e.g., the instrument of the blood coagulation property analysis and calculation unit and/or the result presentation unit).
In one of its aspects, the blood pretreatment unit of the blood sample receiving and pretreatment unit is adapted to remove or counteract the anticoagulant effect of (in particular artificially added) anticoagulant present in the blood sample. In the present invention, the pretreatment of the blood sample means to remove or counteract the anticoagulant effect of the anticoagulant present in the blood sample (in particular artificially added), without affecting the intrinsic coagulation characteristics of the blood to be tested itself.
In one of its aspects, the reaction unit comprises a module for applying a voltage difference across the blood sample and for recording an electrical signal. For example, the reaction unit includes a power source, a plurality of electrodes in contact with blood contained in the reaction unit, and an a/D converter.
In one aspect of the present invention, the blood coagulation property analysis calculation unit may detect an electric signal passing through the blood sample within a measurement duration, in accordance with a Prothrombin Time (PT), an International Normalized Ratio (INR), an Activated Partial Thromboplastin Time (APTT), Fibrinogen (FIB), and a Thrombin Time (TT) of the calculated sample. In one aspect of the present invention, the blood coagulation characteristic analysis and calculation unit comprises a processor, which may be any one of a control logic circuit, a central processing unit, a microprocessor, or other suitable type of processor.
In one aspect of the present invention, the blood pretreatment unit removes or counteracts the anticoagulation effect of sodium citrate. Thus, the blood pretreatment can restore the blood coagulation property of the blood sample containing sodium citrate.
In one embodiment of the present invention, the blood pretreatment unit is made of a filter material. The filter material is a sheet-like porous body having many fine continuous pores communicating from one surface to the other surface. In the present invention, the blood pretreatment unit is a filter material unit through which blood can pass. In one embodiment of the present invention, the pore size of the filtering material allows the free passage of particulate matter such as cells, follicles, etc. in the blood. By controlling the pore size and the liquid passing distance and time of the filter material, the filter material can not generate or basically generate physical adsorption to cells, proteins or nucleic acids, various small molecules or ions in blood when the blood passes through the filter material. Preferably, the material is biologically inert and does not react or inhibit substances in the blood, such as cells, proteins or nucleic acids. In embodiments of the present invention, the filter material typically contains a solid deinstallation material.
In one aspect of the present invention, the material of the blood pretreatment member is a polymer material, such as Polyethersulfone (PES), Polyacrylonitrile (PAN), polyvinylidene fluoride (PVDF), Polystyrene (PS), or polyvinyl chloride (PVC), or glass fiber. In yet another aspect of the present invention, the material of the blood pretreatment member is a hydrophilic material.
In one aspect of the present invention, the blood pretreatment member contains a soluble calcium salt, such as calcium chloride. The soluble calcium salt used in the utility model comprises calcium chloride, calcium gluconate, calcium dihydrogen phosphate, calcium nitrate, calcium bicarbonate, calcium hydrogen sulfate, etc. In one aspect of the invention, the soluble calcium salt is present in solid form within the blood pretreatment member. The soluble calcium salt in the blood pretreatment part is dissolved in the blood when the blood passes through, provides free calcium ions, and can be used for supplementing calcium ions which are reduced or even absent in anticoagulation due to the formation of a difficult-to-dissociate soluble complex with citrate of sodium citrate, thereby removing or offsetting the anticoagulation effect of the sodium citrate.
In one aspect of the present invention, the blood pretreatment member is prepared by contacting a polymeric material with a solution of a soluble calcium salt.
In one aspect of the present invention, the blood pretreatment unit is a filter block disposed above the sample addition hole or in the sample addition hole. The filter block typically has the same cross-section as the well, and thus can be positioned over or within the well. The filter block is configured such that the time and space for the blood sample to pass through the filter block allows the anticoagulant to be removed from the blood sample to substantially contact and react with the anticoagulant contained within the filter block.
In one aspect of the present invention, the blood pretreatment unit is a filtration membrane covering the sampling hole. One end of the filtering membrane covers the sample adding hole, and the other end of the filtering membrane is provided with a sample inlet. After being added from the sample inlet, the blood transversely moves to the sample adding hole through the filter membrane. The filter membrane is configured such that the time and space for the blood sample to travel laterally from the sample inlet to the filter membrane to the sample addition port allows the anticoagulant to be removed from the blood sample to substantially contact and react with the anticoagulant contained within the filter membrane.
In one aspect of the present invention, the apparatus further comprises a processor. Which may be any of a control logic circuit, a central processing unit, a microprocessor, or other suitable type of processor.
In one of its aspects, the apparatus further comprises a computer readable medium. Information or computational methods related to the blood coagulation property may be stored in the computer readable medium.
In one of its aspects, the device further comprises a display that presents information related to the blood coagulation characteristic.
Drawings
The detailed description is set forth with reference to the accompanying drawings.
Fig. 1 is a schematic structural diagram of an exemplary apparatus 301 for detecting blood coagulation characteristics according to the present invention.
Fig. 2A and 2B are schematic structural views of an exemplary test cassette 202 of the apparatus of the present invention. In operation, test cassette 202 is inserted in a horizontal orientation into device 301 for testing blood coagulation properties; fig. 2A and 2B are schematic top plan views of the test cassette. Fig. 2A is an embodiment of the testing cassette of the present invention, wherein the blood pretreatment unit is a filter column disposed above or in the sample well. Fig. 2B shows another embodiment of the test cassette of the present invention, wherein the blood pretreatment unit is a filtration membrane disposed above the sample application hole.
FIGS. 3A to 3C are schematic views showing the structure of a cartridge used in the apparatus in the comparative experiment. Wherein fig. 3A and 3B are test cartridges corresponding to the designs of fig. 2A and 2B, respectively. FIG. 3C is a prior art device employing a test cassette without a blood pretreatment unit.
Detailed Description
For purposes of discussion, some example embodiments are described in the context of test devices and systems for testing blood coagulation properties. However, it will be apparent to those skilled in the art in light of this disclosure that the embodiments herein are not limited to the particular examples provided, but may be extended to other types of devices, apparatuses and systems, and other types of inspections.
The utility model provides a device for detecting blood coagulation characteristic of blood specimen.
Fig. 1 is a schematic structural diagram of an exemplary apparatus for detecting blood coagulation characteristics according to the present invention.
As shown in fig. 1, the apparatus 301 for detecting blood coagulation property includes a blood sample receiving and preprocessing unit 201, a reaction unit 204, a blood coagulation property analysis and calculation unit 316, and a result presentation unit 320.
In the exemplary apparatus for measuring blood coagulation property shown in fig. 1, a blood sample receiving and preprocessing unit 201 includes a blood preprocessing member 203, a loading hole and a transfer channel connected to a reaction unit. The blood sample receiving and pre-processing unit is used to pre-process the original blood sample and then transfer the processed blood sample to the reaction unit 204. The utility model provides a blood sample of device is received and is pretreated the unit and include blood preliminary treatment spare, sample addition mouth and the transfer passage who is connected with the reaction unit.
In the field of medical testing and research, in the testing of blood, after a blood sample (e.g., blood at the tip of an ear lobe or a fingertip, venous blood) is obtained from a subject, in order to prevent the blood sample from coagulating during storage or transfer, the blood is usually subjected to an anticoagulation treatment, such as artificial addition of an anticoagulation agent such as sodium citrate. Therefore, a blood sample for testing blood coagulation property may be subjected to anticoagulation treatment with an anticoagulant artificially added. The utility model discloses in, the preliminary treatment to the blood sample is that the anticoagulant effect of getting rid of or offsetting the artificial anticoagulant that adds to do not influence the intrinsic coagulation property of blood itself that awaits measuring.
The device provided by the utility model is used for detecting the coagulation property of the blood of the testee. Coagulation of blood refers to the process by which blood forms a blood clot, which generally includes three stages: during the first phase, vessel wall injury or trauma triggers the attachment and activation of platelets; in a second phase, the activated platelets provide a surface for aggregation and activation of coagulation factors and complexes; in the third phase, coagulation factors interact to generate thrombin, which converts fibrinogen (fibrinogen) to fibrin (fibrin). Fibrin strands bind the aggregated platelets to help consolidate the platelet-fibrin hemostatic plug. The second and third stages of blood coagulation may be referred to as coagulation cascade reactions (coagulation cascade) for the interaction between each of the coagulation factors. Since thrombin is formed in these stages, these are the major stages of coagulation. Thrombin is a blood coagulation effector enzyme having biologically important functions, such as activation of platelets, conversion of fibrinogen to the fibrin network, and feedback amplification of coagulation. The coagulation cascade reaction can be generalized into three pathways: intrinsic pathway, extrinsic pathway and common pathway. The intrinsic pathway may be triggered by surface contact, while the extrinsic pathway may be triggered by a tissue/cell defect. Both of which can lead to the formation of thrombin. In the common pathway, thrombin converts fibrinogen to fibrin, which can then form a crosslinked fibrin network.
Coagulation properties of blood include, without limitation, Prothrombin Time (PT), Activated Partial Thrombin Time (APTT), Activated Clotting Time (ACT), fibrinogen content (FIB), and Thrombin Time (TT, Thrombin Time).
In the exemplary apparatus for measuring blood coagulation property shown in fig. 1, the reaction unit 204 is used to make the blood to be measured perform biochemical or physiological reaction for obtaining information related to blood coagulation property. For example, by a method as disclosed in chinese patent CN103543191B, in which a voltage difference is given to a blood sample, and by measuring the current response due to the coagulation reaction in the blood sample with respect to time during blood coagulation, it is possible to determine the blood coagulation characteristics of blood such as Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Activated Clotting Time (ACT), fibrinogen content (FIB) and Thrombin Time (TT). One of the principles of the method is based on: during solidification, there is a gradual increase in internal friction for conductivity, resulting in cumulative conduction energy loss.
In an embodiment of the present invention, the whole or part of the blood sample receiving and preprocessing unit and the reaction unit of the device for detecting blood coagulation property of the present invention is set as the fixed structure of the device 301.
In another embodiment of the present invention, all or part of the blood sample receiving and preprocessing unit and the reaction unit of the apparatus for detecting blood coagulation characteristics of the present invention are provided in the form of a test cartridge detachably connected to the main body of the apparatus 301. Preferably, the test cartridge is a disposable test cartridge. Thus, the device for receiving and containing a blood sample can be disposable, reducing the risk of sample contamination and distortion of the test results.
In the exemplary apparatus for measuring blood coagulation property shown in fig. 1, a partial structure of the blood sample receiving and preprocessing unit and the reaction unit forms a test cartridge 202, which is inserted into a test cartridge receiving groove 304 of a main body of the apparatus 301.
Fig. 2A and 2B are schematic structural views of an exemplary test cassette 202 of the device of the present invention. In operation, test cassette 202 is inserted in a horizontal orientation with the device for testing blood coagulation properties; i.e., fig. 2A and 2B are top plan views of the test cassette. Fig. 2A shows an embodiment of the testing cassette of the present invention, wherein the blood pretreatment unit is a filter block 2031 disposed above the sample well or in the sample well. Fig. 2B shows another embodiment of the test cassette of the present invention, wherein the blood pretreatment unit is a filtration membrane 2032 disposed above the well.
As shown in fig. 1 and fig. 2A and 2B, the blood sample receiving and preprocessing unit 201 includes a blood preprocessing member 203. The utility model discloses in, the preliminary treatment to the blood sample means that the anticoagulant effect of the artificial anticoagulant that adds that exists in the blood sample is got rid of or offset to do not influence the intrinsic coagulation property of blood itself that awaits measuring. Generally, this is accomplished by contacting the blood sample with a deiagulate that reacts with the artificially added anticoagulant to be removed. In one exemplary embodiment of the present invention, the blood sample to be treated is a blood sample containing sodium citrate, and the blood pretreatment member 203 is used to remove or offset the anticoagulation effect of sodium citrate.
In one embodiment of the present invention, the blood pretreatment unit is made of a filter material. The filter material is a sheet-like porous body having many fine continuous pores communicating from one surface to the other surface. Examples of such porous bodies include membranes or blocks made of polymer materials (for example, PES, PAN, PVDF, PS, and PVC), and glass fibers. In one embodiment of the present invention, the pore size of the filtering material allows the free passage of particulate matter such as cells, follicles, etc. in the blood. By controlling the pore size and the liquid passing distance and time of the filter material, the filter material can not generate or basically generate physical adsorption to cells, proteins or nucleic acids, various small molecules or ions in blood when the blood passes through the filter material. Preferably, the material is biologically inert and does not react or inhibit substances in the blood, such as cells, proteins or nucleic acids. In embodiments of the present invention, the filter material typically contains a solid deinstallation material.
In one embodiment of the present invention, the blood pretreatment member comprises a solid soluble calcium salt. The soluble calcium salt used in the utility model comprises calcium chloride, calcium gluconate, calcium dihydrogen phosphate, calcium nitrate, calcium bicarbonate, calcium hydrogen sulfate, etc. In one embodiment of the present invention, the blood pretreatment unit contains calcium chloride. The soluble calcium salt can release free calcium ions in blood, and the calcium ions and citrate radicals of the sodium citrate form a non-dissociative soluble complex compound, so that the sodium citrate in the anticoagulation blood is reduced, and the anticoagulation effect of the sodium citrate is removed or counteracted.
The soluble calcium salt may be bound by adsorption to the filter material forming the blood pretreatment member. For example, a filter material containing a soluble calcium salt can be obtained by soaking the filter material in a solution containing the soluble calcium salt, followed by drying, and then the filter material can be processed into a desired shape.
The utility model discloses an in an embodiment, blood preliminary treatment spare has the cross section the same with the application of sample hole for setting up the filter block in application of sample hole top or application of sample hole.
As shown in fig. 2A, the test cartridge 202 includes a loading well 212 and a transfer channel 210 connected to a reaction unit. In operation, the test cassette 202 is inserted with the device for testing blood coagulation properties in a horizontal orientation, i.e., the filter column is oriented perpendicular to the horizontal in operation. A filter block 2031 is arranged above the sample adding hole 212, and the top of the filter block is a sample inlet. When the original blood sample is added to the sample inlet, the blood enters the filter block 2031, passes through the filter column under gravity and capillary action into the sample addition well 212, and flows to the reaction zone through the microfluidic transport channel 210. The filter block typically has the same or similar cross-section as the well and may be positioned over the well or within the well. The filter block is configured such that the time and space for the blood sample to pass through the filter block allows the anticoagulant to be removed from the blood sample to be substantially contacted and reacted with the deiagulant.
In one embodiment of the present invention, the blood pretreatment unit is a filtration membrane disposed above the sampling hole.
As shown in fig. 2B, the test cartridge 202 includes a sample well 212 and a transfer channel 210 connected to the reaction unit, a filter membrane 2032 is disposed above the sample well 212, one end of the filter membrane covers the sample well 212, and the other end of the filter membrane is provided with a sample inlet 205. After being introduced from the inlet, the blood is moved laterally through the filter to the sample well 212. The filter membrane is configured such that the time and space for the blood sample to move laterally from the sample inlet through the filter membrane to the sample application well allows the anticoagulant to be removed from the blood sample to be substantially contacted and reacted with the anticoagulant.
As shown in fig. 1 and 2A and 2B, the test cartridge 202 also includes a reaction zone 204, encompassed by dashed line 206, having a reagent or reagents 208 or other substance selected for one or more types of tests. Typically, the different assays (e.g., PT, APTT, ACT, FIB or TT) have their own reagents 208 or other substances suitable for detecting specific characteristics. As one example, reagents 208 may be pre-applied (e.g., printed, placed, etc.) and immobilized at reaction zone 204.
The test cartridge 202 may also include a plurality of electrodes 214 to form an electrochemical cell. For example, a first electrode 216 may be coupled to a first portion 218 of reaction zone 204 and a second electrode 220 may be coupled to a second portion 222 of reaction zone 204. A third electrode 224 is also connected to reaction zone 204. In this example, the electrochemical cell at reaction zone 204 is comprised of three electrodes, e.g., a working electrode, a counter electrode, and a reference electrode. In other examples, the counter electrode and the reference electrode may be combined to provide a two-electrode configuration.
Accordingly, it can be seen that when blood from a sample port enters reaction zone 204, blood sample 104 is positioned between a plurality of electrodes, such as first electrode 216 and second electrode 220. Further, in examples where a reagent or other substance is used during the testing of the blood sample, blood sample 104 may interact with reagent 208 or other substance in reaction zone 204. Further, although only a single electrochemical cell is shown in this example, in other examples, multiple electrochemical cells may be included to provide multiple reaction zones 204. For example, different reaction zones 204 may include different types of reagents 208 or substances suitable for different types of assays. These reaction zones may be connected to a single sample receiver 212 by channels.
Within the reaction zone 204, the blood sample reacts with the reagent 208, which may trigger a series of biochemical reactions that result in coagulation. In reaction zone 204, blood sample 104 is in contact with a plurality of electrodes 214. When test cartridge 202 is inserted into device 301, electrodes 214 located in reaction zone 204 and blood sample 104 become the galvanic part of the complete electrical circuit for testing blood sample 104. For example, the apparatus may apply a voltage difference across the electrodes 214 to detect an electrical signal at the output terminals of the circuit over a period of time (i.e., a measurement duration) in order to obtain a plurality of measurements that represent a function of time (i.e., a measured function of time).
The device 301 for detecting blood coagulation characteristics provided by the present invention further has a housing 303 (not shown in the figures). The housing may separate the instrument interior from the atmosphere to avoid sample contamination and part damage. The housing panels are typically made of a metallic material. The housing may have a sample window that can be opened and closed for placing and removing a sample. In addition, the housing may have an external device interface connected to an external device, a display screen displaying an operation interface, various manipulation switches, keys or buttons, and the like.
As shown in FIG. 1, device 301 also includes a test cartridge receiving slot 304 and a heater 306. Heater 306 may ensure that blood sample 104 is maintained at a consistent temperature at the time of testing to ensure consistent testing across multiple samples.
The apparatus 301 may also include a plurality of electrical connections 308 for connecting the electrodes of the test cartridge 202 with the circuitry 310 of the device 302. For example, the electrodes 214 may be connected to a power source 312 and an analog/digital converter 314. Power source 312 may provide a voltage differential across blood sample 104 during testing of blood sample 104 in reaction zone 214 of test cartridge 202. A/D converter 314 may measure the resulting electrical signal, for example, at an output terminal. In some cases, the output terminals may correspond to one or more of the electrodes 214.
The device 301 may also include one or more processors 316, one or more computer-readable media 318, a display 320, a power adapter port 322, and one or more communication interfaces 324, such as an external data port or other suitable communication interface. Processor 316 may be any of a control logic circuit, a central processing unit, a microprocessor, or other suitable type of processor. In some examples, each processor 316 may itself include one or more processors or processing cores.
Depending on the configuration of device 302, computer-readable media 318 may be examples of tangible, non-transitory computer storage media and may include volatile and non-volatile memory and/or removable and non-removable media implemented in any type of technology for storing information, such as computer-readable instructions, data structures, program modules, or other data. Such computer-readable media 318 may include, but is not limited to, RAM, ROM, EEPROM, flash memory, or other computer-readable media technology, computer storage technology, or any other medium that may be used to store information and that may be accessed by processor 316 either directly or through another computing device. Accordingly, computer-readable media 318 may include computer storage media capable of storing and maintaining instructions, modules, or components executable by processor 316.
Computer-readable media 318 may be used to store any number of functional components executable by processor 316. In some implementations, these functional components include instructions, code, or programs that are executable by the processor 316 and that, when executed, implement operational logic for performing the actions attributed to the device 302. The functional components of the device 302 maintained in the computer readable medium 318 may include a test module 326 executable by the processor 316 to perform a test on the blood sample, such as applying a voltage differential across the blood sample and obtaining a measurement of an electrical signal. The functional components may also include an analysis module 330 that may be executed by the processor 316 to perform some of the functions described herein, such as determining the time measurement function 114, one or more corresponding cumulative characteristics 116, and/or the blood coagulation characteristic 118. For example, analysis module 330 may also determine blood coagulation characteristics based at least in part on cumulative characteristics 116 and/or measurement 112 or measurement function 114 of time. Further, the computer-readable medium 318 may store data such as the measurements 112, the measured function of time 114, the cumulative characteristic 116, the blood coagulation characteristic 118, or information related thereto. Further, depending on the type of device 302, the computer-readable medium 318 may also optionally include other functional components and data, such as user interface modules, communication modules, medical histories, past blood coagulation test results or other modules, applications, programs, drivers, data, and so forth.
Measurements 112 obtained by device 301 for blood sample 104 may be stored in computer-readable medium 318 and analyzed, for example, by execution of analysis module 330 by processor 316. The analysis module 330 may determine the magnitude of the cumulative characteristic 116 of the measurement function 114. The cumulative characteristic 116 may be empirically derived or selected prior to obtaining the measurement 112, or in some cases, prior to manufacturing the device 302. For example, the criteria for selecting an appropriate cumulative characteristic 116 are typically: a good correlation with the blood coagulation property 118 is obtained so that the accumulated property 116 can be used to determine the blood coagulation property 118.
In some examples, the processing of measurement function 114, accumulated characteristic 116, and/or blood coagulation characteristic 118 to determine time may be performed by analysis module 330 executed by processor 316 on device 301. In other examples, some or all of the processing may be performed by the external computing device 328. For example, device 302 may provide measurements 112 to computing device 328, and computing device 328 may execute analysis module 330 on a processor of computing device 328 to determine measurement function 114 of time, apply cumulative characteristic 116, and/or determine blood coagulation characteristic 118. In this case, verification module 326 or other suitable application or communication module on device 302 may communicate with computing device 328 over connection 332 to provide measurement 112 to computing device 328. In other examples, the computing device 328 may expose a programming interface or API (application programming interface) that the device 302 may use to provide the measurements 112. In other examples, rather than providing measurements 112, device 302 may provide blood coagulation characteristic 118 or information related to the blood coagulation characteristic to computing device 328.
The communication interface 324 may support wired and/or wireless connectivity 332 to various networks, such as a cellular network, radio communication, Wi-Fi network, short-range or near-field network (e.g., a WLAN network)
) Infrared signals, local area networks, wide area networks, the internet, direct cable connections, and the like. As one example, communication interface 324 may include a USB (Universal Serial bus) port, an IEEE 802.3 port, or other wired connection. In other examples, the communication interface 324 may allow the apparatus 301 to access a wireless communication network or device.
As shown in fig. 1, the apparatus 301 further comprises a display 320, and the display 320 may be a passive, emissive, or any other form of display. In some examples, display 320 may include any suitable type, such as a liquid crystal display, a plasma display, a light emitting diode display, an organic light emitting diode display, and so forth. Further, in some examples, display 320 may have a touch sensor associated therewith to enable touch input from a user. Moreover, in other examples, the apparatus 301 may not include a display.
Example 2 detection and comparison of coagulation properties of blood:
detecting items: prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Activated Clotting Time (ACT), fibrinogen content (FIB), and Thrombin Time (TT)
1. The instrument comprises the following steps:
produced and sold by Shenzhen microbial technology shares Limited
Electrochemical detector (model Q-1, Guangdong instrument notes standard 20172401103), and right the instrument improves and obtains the utility model provides a device.
According to Q-1 type
The manual of the electrochemical detector can carry out in-vitro quantitative detection on Prothrombin Time (PT)/Activated Partial Thromboplastin Time (APTT)/Fibrinogen (FIB)/Thrombin Time (TT) on fresh anticoagulated venous whole blood or capillary whole blood of a human body. The apparatus has a structure including the apparatus 301 as described in embodiment 1 (shown in fig. 1 and fig. 2A and 2B) and the respective portions of the test cassette 202 therein except for the blood sample pretreatment member 203, that is, including the blood sample receiving and pretreatment unit 201, the reaction unit 204, the blood coagulation characteristic analysis calculation unit 316, and the result presentation unit 320, but not including the blood sample pretreatment member 203.
In use, the quad test card is inserted into a Q-1 type
The test card slot (corresponding to the test cartridge receiving slot 304 in FIG. 1) of the electrochemical meter allows a blood sample to enter the reaction area 204 through the transfer channel 210 after the blood sample is added to the sample addition hole 212. In operation of the instrument, a constant voltage is output to the electrode 214. Within the reaction zone, blood is induced to undergo a series of biochemical reactions to begin clotting. The electrochemical detector monitors the blood coagulation process and generates the change of a current signal, and a blood coagulation characteristic analysis calculator arranged in the instrument generates a blood coagulation curve with the change of current and time according to a set program. The curve is changed and corresponding characteristics (height, area, etc.) are generated along with the activation of coagulation factors during coagulation and the conversion of fibrinogen into fibrin, the coagulation characteristics of the curve are analyzed and the Prothrombin Time (PT), the International Normalized Ratio (INR), the Activated Partial Thromboplastin Time (APTT), the Fibrinogen (FIB) and the Thrombin Time (TT) of the sample are calculated, and the results are reported on the screen of the detector.
In the present embodiment, for
Electrochemical detector Q-1 type is improved, has added extra blood pretreatment unit and has obtained the utility model discloses a device particularly, has increased the pretreatment unit who has the anticoagulation of sodium citrate in getting rid of the anticoagulation that contains sodium citrate.
Fig. 3B and fig. 3C show the schematic structure of the detection card of the device of the present invention with two different designs.
As shown in fig. 3B, a filter column 2031 is provided above the sample application hole 212 of the test card. In operation, the test card is inserted in a horizontal orientation
The electrochemical detector, namely the filter column, is vertical to the horizontal plane in operation. Adding anticoagulant blood containing sodium citrate dropwise to the top of the filter column, allowing the blood to enter the filter column, pass through the filter column under capillary action, enter the sample adding hole, and flow to the reaction region through the microfluidic conveying channel.
As shown in fig. 3C, a filter membrane 2032 is provided above the sample hole 212 of the detection card, one end of the filter membrane covers the sample hole, and the other end of the membrane is a sample inlet 205. Adding anticoagulant blood containing sodium citrate dropwise to the position of the sample inlet, absorbing the blood by the filter membrane, transversely moving the blood to the sample adding hole through the filter membrane, and flowing to the reaction area through the microfluidic conveying channel.
2. Preparation of Filter columns/membranes
Membrane material of the filter column:
filter membrane material
Calcium chloride loading treatment is carried out on the filter column/filter membrane
Calcium chloride (purity > 96%, national drug group chemical agents limited, china) was dissolved in deionized water to prepare a 0.05mol/L aqueous solution. And respectively soaking the membrane materials in calcium chloride solution for 10min, and drying the soaked membrane materials at 45 ℃ for 8h for later use.
3. Blood samples were collected from recruited volunteers, peripheral blood was collected by finger prick, and control samples and test samples (anticoagulated with sodium citrate) were prepared from blood samples of the same volunteer.
Control samples: peripheral blood of origin
Testing a sample: 3.2 percent of sodium citrate, wherein the ratio of sodium citrate to raw blood is 1: 9;
4. detection of
Test samples (10 cases) were tested with the instrument and setup as shown in fig. 3A. The results are all shown as "No Coag", i.e., No blood sample clotting could be detected.
The control sample and the test sample were subjected to the test by the apparatus and setting shown in FIG. 3B (5 cases, filtration column: sample Nos. 1 to 5) or FIG. 3C (5 cases, filtration membrane: samples 6 to 10), respectively.
The detection results are as follows:
the bias analysis was as follows:
| sample numbering | INR | APTT | FIB | TT |
| 1 | 3.6％ | -1.5％ | -3.0％ | 2.7％ |
| 2 | 3.6％ | 3.8％ | -1.6％ | -1.2％ |
| 3 | 3.1％ | -1.9％ | -5.0％ | -0.7％ |
| 4 | -9.1％ | -4.7％ | -1.2％ | 2.7％ |
| 5 | -6.0％ | 6.0％ | 1.8％ | -2.9％ |
| 6 | 4.7％ | -2.2％ | -3.2％ | -6.8％ |
| 7 | 2.2％ | -2.8％ | -3.7％ | -1.5％ |
| 8 | -4.3％ | -3.0％ | 6.2％ | 6.0％ |
| 9 | 2.5％ | 2.3％ | -7.3％ | -0.4％ |
| 10 | -2.7％ | 1.2％ | 2.7％ | -2.7％ |
And (4) analyzing results: from the analysis of fingertip blood stoste and anticoagulation sodium citrate test result, anticoagulation sodium citrate passes through the utility model discloses an instrument and setting up the back, the coagulation function resumes, and fingertip blood and anticoagulation test INR/APTT/FIB/TT result deviation all is in 10%.
Claims (10)
1. An apparatus for measuring blood coagulation properties of a blood sample, said apparatus comprising:
the blood sample receiving and preprocessing unit comprises a blood preprocessing part, a sample adding hole and a conveying channel connected with the reaction unit; wherein the blood pretreatment member is used to remove or counteract the anticoagulant effect of an anticoagulant present in a blood sample; and
a reaction unit in which blood produces a coagulation process.
2. The apparatus of claim 1, further comprising:
a blood coagulation characteristic analysis calculation unit; and
and a result presenting unit.
3. The device of claim 1 or 2, wherein the blood pretreatment member is prepared from a filter material through which blood can pass.
4. The device of claim 3, wherein the material of the blood pretreatment member is a polymeric material.
5. The device according to claim 4, wherein the material of the blood pretreatment member is a polymer material selected from Polyethersulfone (PES), Polyacrylonitrile (PAN), polyvinylidene fluoride (PVDF), Polystyrene (PS), polyvinyl chloride (PVC), or glass fiber.
6. The device of claim 1, wherein the blood pretreatment member removes or counteracts anticoagulation by sodium citrate.
7. The device of claim 6, wherein the blood pretreatment member comprises a soluble calcium salt.
8. The device of claim 7, wherein the blood pretreatment member comprises calcium chloride.
9. The device of claim 1, wherein the blood pretreatment member is a filter block disposed over or within the loading well.
10. The device of claim 1, wherein the blood pretreatment member is a filter membrane covering over the loading aperture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202021560467.9U CN214374840U (en) | 2020-07-31 | 2020-07-31 | Device for detecting blood coagulation characteristics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202021560467.9U CN214374840U (en) | 2020-07-31 | 2020-07-31 | Device for detecting blood coagulation characteristics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN214374840U true CN214374840U (en) | 2021-10-08 |
Family
ID=77931949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202021560467.9U Active CN214374840U (en) | 2020-07-31 | 2020-07-31 | Device for detecting blood coagulation characteristics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN214374840U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111856042A (en) * | 2020-07-31 | 2020-10-30 | 深圳微点生物技术股份有限公司 | Device for detecting blood coagulation properties and its application |
-
2020
- 2020-07-31 CN CN202021560467.9U patent/CN214374840U/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111856042A (en) * | 2020-07-31 | 2020-10-30 | 深圳微点生物技术股份有限公司 | Device for detecting blood coagulation properties and its application |
| WO2022022280A1 (en) * | 2020-07-31 | 2022-02-03 | 深圳微点生物技术股份有限公司 | Device for detecting blood coagulation characteristics and application of device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9551699B2 (en) | Testing of blood coagulation characteristics | |
| US20100200400A1 (en) | Embedded bodily fluid analysis device | |
| JP7544917B2 (en) | Sensor device and method of use | |
| JP5379809B2 (en) | Automatic method and apparatus for detecting erroneous sample collection in clinical analysis | |
| DE69828319T2 (en) | METHOD AND APPARATUS FOR MEASURING BLOOD COAGULATION OR LYSIS WITH THE HELP OF VISCOSITY CHANGES | |
| Guan et al. | An integrated platform for fibrinogen quantification on a microfluidic paper-based analytical device | |
| CN107923865A (en) | Utilize the Allergic skin test device of electrochemical detection method | |
| CN214374840U (en) | Device for detecting blood coagulation characteristics | |
| US20230341424A1 (en) | Device for detecting blood coagulation characteristics and application of device | |
| Zhou et al. | An integrated leather-based fluid transport wearable sweat device for electrolyte balance monitoring | |
| JP3149597B2 (en) | Body fluid component measurement device | |
| JPH0526846A (en) | Method for continuously measuring concentrations of chlorine ion and bromine ion in body fluid using same liquid and same electrode | |
| US20210260589A1 (en) | Method and Apparatus for Measuring Blood Coagulation | |
| CN204731241U (en) | A kind of electrochemical process blood testing paper slip | |
| RU2413768C2 (en) | Method of determining dna-hydrolysing activity of molecules and device for its realisation | |
| US12436160B2 (en) | Method of detecting an obstruction in a fluid analyzer | |
| EP3814773B1 (en) | Contoured sample path for fluid analyzer | |
| US20250044252A1 (en) | Sensor assembly with wicking member for liquid junction wet up | |
| EP3607311B1 (en) | Lab-on-a-chip diagnosis device | |
| CN115165996A (en) | Urine detection method and device | |
| Adekola et al. | The agreement of Point-of-Care and Standard Laboratory Electrolyte and Glucose Analysis in critically ill Patients | |
| EP3983787A1 (en) | System and method of measurement and calibration of analyte testing | |
| JPS60185155A (en) | Analysis of glucose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |